Methods and kits for detecting antigen-induced memory cd8+ t cells
AssigneesInserm (Isntitut National De La Sante Et De La Recherche MéDicale), Universite Claude Bernard Lyon 1, Centre National de la Recherche Scientifique (CNRS)
InventorsJacqueline MARVEL, Sophia DJEBALI, Morgan GRAU, Julien MAFILLE, Yann LEVERRIER
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and kits for detecting antigen-induced memory CD8+ T cells. In particular, the invention relates to a method for determining the presence of a population of antigen-induced memory CD8+ T cells in a sample, comprising i) isolating the population of the CD8+ T cells from the sample and ii) detecting in said population the expression of CCL5 or NKG2D and iii) concluding that at least one population of antigen-induced memory CD8+ T cells is present in a sample when CCL5 or NKG2D is detected as step ii).
Claims13
A method for determining the presence of a population of antigen-induced memory CD8+ T cells in a sample, comprising
- i) isolating a population of CD8+ T cells from the sample
- ii) detecting in said population expression of CCL5 or NKG2D and
- iii) concluding that at least one population of said antigen-induced memory CD8+ T cells is present in a said sample when CCL5 or NKG2D is detected as in step ii).
A method for determining whether a subject has developed a memory T cell response in a context of a disorder selected from the group consisting of infections with a pathogenic organism, cancers, allergies, and autoimmune disorders, comprising
- i) isolating a population of CD8+ T cells from said subject,
- ii) detecting in said population expression of CCL5 or NKG2D, and
- iii) concluding that said subject has developed a memory T cell response if CCL5 or NKG2D is detected in at least one population of said CD8+ T cells.
A method for determining the efficacy of a treatment for a disorder in a subject, wherein said disorder is selected from the group consisting of infections with a pathogenic organism, cancers, allergies, and autoimmune disorders, comprising
- i) treating said subject for said disorder,
- ii) isolating a population of CD8+ T cells from said subject,
- iii) detecting expression of CCL5 or NKG2D in said population of CD8+ T cells, and
- iv) concluding that said subject has developed a memory T cell response and thus that said treatment is efficacious if CCL5 or NKG2D is detected in said population of said CD8+ T cells.
A method for testing efficacy of a vaccine
- i) vaccinating a subject
- ii) isolating a population of CD8+ T cells from said vaccinated subject
- iii) detecting expression of CCL5 or NKG2D in said population of CD8+ T cells and
- iv) concluding that said vaccinated subject has developed a memory T cell response and thus that said vaccine is efficacious if CCL5 or NKG2D is detected in at least one population of said CD8+ T cells.
A method for screening a combination of antigens and/or immunoadjuvants for the preparation of a vaccine preparation, comprising
- i) administering said combination of antigens and/or immunoadjuvants to a subject,
- ii) isolating a population of CD8+ T cells from said subject,
- iii) detecting expression of CCL5 or NKG2D in said population of CD8+ T cells, and
- iv) concluding that said subject has developed a memory T cell response and thus that said combination of antigens and/or immunoadjuvants is efficacious and suitable for use in a vaccine if CCL5 or NKG2D is detected in at least one population of said CD8+ T cells.
Dependencies are inferred from the claim text.